Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Dare Bioscience, Inc. (NASDAQ:DARE) was the target of a large increase in short interest in May. As of May 15th, there was short interest totaling 791,165 shares, an increase of 120.9% from the April 30th total of 358,082 shares. Based on an average trading volume of 1,271,415 shares, the short-interest ratio is currently 0.6 days. Approximately 5.5% of the company’s stock are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Dare Bioscience during the 3rd quarter worth $37,000. Raymond James Financial Inc. lifted its position in Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 13,650 shares during the last quarter. Finally, LPL Financial LLC acquired a new position in shares of Dare Bioscience during the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

Dare Bioscience Trading Down 2.2%

Dare Bioscience stock traded down $0.05 on Friday, reaching $2.23. 170,241 shares of the stock were exchanged, compared to its average volume of 844,800. The stock has a market cap of $33.41 million, a PE ratio of -2.35 and a beta of 1.09. Dare Bioscience has a twelve month low of $1.27 and a twelve month high of $9.19. The firm has a fifty day moving average price of $2.15 and a two-hundred day moving average price of $1.94.

Dare Bioscience (NASDAQ:DARE) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.13. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.03 million. Equities analysts anticipate that Dare Bioscience will post -0.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on DARE shares. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.